|
|
|
|
|
Cyproheptadine
drug data and news
Cyproheptadine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cyproheptadine | ||
| Brand Names/Synonyms | Cypoheptadine; Cyproheptadiene; Cyproheptadine; Cyproheptadine Hcl; Dibenzosuberonone/Cyproheptadine; Dronactin; Eiproheptadine; MK 141; Periactin; Periactine; Periactinol; Peritol | ||
| Indication | For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cyproheptadine is a piperidine antihistamine. Unlike other antihistamines, this drug also antagonizes serotonin receptors. This action makes Cyproheptadine useful in conditions such as vascular headache and anorexia. Cyproheptadine does not prevent the release of histamine but rather competes with free histamine for binding at HA-receptor sites. Cyproheptadine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. Most antihistamines possess significant anticholinergic properties, but Cyproheptadine exerts only weak anticholinergic actions. Blockade of central muscarinic receptors appears to account for Cyproheptadine's antiemetic effects, although the exact mechanism is unknown. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite. Cyproheptadine also has been used to counter vascular headaches, which many believe are caused by changes in serotonin activity, however it is unclear how Cyproheptadine exerts a beneficial effect on this condition. | ||
| Mechanism Of Action | Cyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. | ||
| Cyproheptadine News (When available) |
Less depressed but also less sexed Nov 29, 2005 The Aging Equine Nov 12, 2005 Vet bills set to fall this November Sep 16, 2005 Idiopathic Intracranial Hypertension Presenting With Psychiatric ... Sep 24, 2005 Many meds don't mix with the sun Sep 21, 2005 Woman arraigned on drug charges Sep 1, 2005 Proprietary Chinese medicine recalled Aug 5, 2005 Acute Akathisia Associated With Quetiapine Use Jul 6, 2005 Acute Akathisia Associated With Quetiapine Use Jul 6, 2005 Age-Defying Equines Jun 1, 2005 The Aging Equine May 28, 2005 Serotonin Syndrome Associated With Linezolid Treatment After ... Apr 26, 2005 Serotonin Syndrome Associated With Linezolid Treatment After ... Apr 26, 2005 Practice Guidelines for Management of Migraine in Children and ... Apr 1, 2005 AAEP Convention 2004: Horseman's Day--Cushings Feb 14, 2005 The Aging Equine Feb 28, 2005 | ||
| Dosage Forms | SYRUP;TABLET | ||
| Drug_Category | Anti-allergic Agents; Gastrointestinal Agents; Antipruritics; Antihistamine derivatives; ATC:R06AX02 | ||
| Absorption | Well absorbed after oral administration. | ||
| Interactions |
Interactions for Cyproheptadine: MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines. Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C21H21N | ||
| Molecular Weight | 287.398 g/mol | ||
| Smiles String | CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1 | ||
| Melting Point | 215-217 °C | ||
| Water Solubility | Soluble | ||
| State | Solid | ||
| LogP/Hphobicity | 4.682 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic (cytochrome P-450 system) and some renal. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 96 to 99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cyproheptadine.html http://www.rxlist.com/cgi/generic2/cyprohept.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00033 | ||
| CAS Registry Number | 129-03-3 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:597387 | ||
| PharmGKB ID | PA449169 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2245668 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |